Regulus Therapeutics, an early stage biotech developing microRNAs treatments for multiple serious diseases, raised $45 million by offering 11.3 million shares at $4 per share. The company, which was previously expecting to raise $50 million by offering 4.5 million shares at a range of $10 to $12, revised its terms this morning in an amendment filed with the SEC. Regulus Therapeutics listed on the NASDAQ under the symbol RGLS and is trading up about 14% today. Lazard Capital Markets, Cowen & Company and BMO Capital Markets acted as lead managers on the deal.
